Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

330 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Characterization of discordance between mismatch repair deficiency and microsatellite instability testing may prevent inappropriate treatment with immunotherapy.
Geurts BS, Zeverijn LJ, van Berge Henegouwen JM, van der Wijngaart H, Hoes LR, de Wit GF, Spiekman IA, Battaglia TW, van Beek DM, Roepman P, Jansen AM, de Leng WW, Broeks A, Labots M, van Herpen CM, Gelderblom H, Verheul HM, Snaebjornsson P, Voest EE. Geurts BS, et al. Among authors: voest ee. J Pathol. 2024 Jul;263(3):288-299. doi: 10.1002/path.6279. Epub 2024 May 15. J Pathol. 2024. PMID: 38747304
Are tumours angiogenesis-dependent?
Verheul HM, Voest EE, Schlingemann RO. Verheul HM, et al. Among authors: voest ee. J Pathol. 2004 Jan;202(1):5-13. doi: 10.1002/path.1473. J Pathol. 2004. PMID: 14694516 Review.
Effective strategies for management of hypertension after vascular endothelial growth factor signaling inhibition therapy: results from a phase II randomized, factorial, double-blind study of Cediranib in patients with advanced solid tumors.
Langenberg MH, van Herpen CM, De Bono J, Schellens JH, Unger C, Hoekman K, Blum HE, Fiedler W, Drevs J, Le Maulf F, Fielding A, Robertson J, Voest EE. Langenberg MH, et al. Among authors: voest ee. J Clin Oncol. 2009 Dec 20;27(36):6152-9. doi: 10.1200/JCO.2009.22.2273. Epub 2009 Nov 9. J Clin Oncol. 2009. PMID: 19901116 Clinical Trial.
Phase I evaluation of cediranib, a selective VEGFR signalling inhibitor, in combination with gefitinib in patients with advanced tumours.
van Cruijsen H, Voest EE, Punt CJ, Hoekman K, Witteveen PO, Meijerink MR, Puchalski TA, Robertson J, Saunders O, Jürgensmeier JM, van Herpen CM, Giaccone G. van Cruijsen H, et al. Among authors: voest ee. Eur J Cancer. 2010 Mar;46(5):901-11. doi: 10.1016/j.ejca.2009.12.023. Epub 2010 Jan 12. Eur J Cancer. 2010. PMID: 20061136 Clinical Trial.
Phase I evaluation of telatinib, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in combination with irinotecan and capecitabine in patients with advanced solid tumors.
Langenberg MH, Witteveen PO, Roodhart JM, Verheul HM, Mergui-Roelvink M, van der Sar J, Brendel E, Laferriere N, Schellens JH, Voest EE. Langenberg MH, et al. Among authors: voest ee. Clin Cancer Res. 2010 Apr 1;16(7):2187-97. doi: 10.1158/1078-0432.CCR-09-2436. Epub 2010 Mar 16. Clin Cancer Res. 2010. PMID: 20233884 Clinical Trial.
Targeted Next Generation Sequencing as a Reliable Diagnostic Assay for the Detection of Somatic Mutations in Tumours Using Minimal DNA Amounts from Formalin Fixed Paraffin Embedded Material.
de Leng WW, Gadellaa-van Hooijdonk CG, Barendregt-Smouter FA, Koudijs MJ, Nijman I, Hinrichs JW, Cuppen E, van Lieshout S, Loberg RD, de Jonge M, Voest EE, de Weger RA, Steeghs N, Langenberg MH, Sleijfer S, Willems SM, Lolkema MP. de Leng WW, et al. Among authors: voest ee. PLoS One. 2016 Feb 26;11(2):e0149405. doi: 10.1371/journal.pone.0149405. eCollection 2016. PLoS One. 2016. PMID: 26919633 Free PMC article.
Molecular Tumor Boards: current practice and future needs.
van der Velden DL, van Herpen CML, van Laarhoven HWM, Smit EF, Groen HJM, Willems SM, Nederlof PM, Langenberg MHG, Cuppen E, Sleijfer S, Steeghs N, Voest EE. van der Velden DL, et al. Among authors: voest ee. Ann Oncol. 2017 Dec 1;28(12):3070-3075. doi: 10.1093/annonc/mdx528. Ann Oncol. 2017. PMID: 29045504 Free article.
Platelet function is disturbed by the angiogenesis inhibitors sunitinib and sorafenib, but unaffected by bevacizumab.
Walraven M, Homs MYV, van der Veldt AAM, Dekker H, Koldenhof J, Honeywell R, Barendrecht A, Sebastian SAE, Parr N, Koekman AC, Voest EE, Roest M, Korporaal SJA, Verheul HMW. Walraven M, et al. Among authors: voest ee. Angiogenesis. 2018 May;21(2):325-334. doi: 10.1007/s10456-018-9598-5. Epub 2018 Mar 12. Angiogenesis. 2018. PMID: 29532289 Free PMC article.
Personalised reimbursement: a risk-sharing model for biomarker-driven treatment of rare subgroups of cancer patients.
van Waalwijk van Doorn-Khosrovani SB, Pisters-van Roy A, van Saase L, van der Graaff M, Gijzen J, Sleijfer S, Hoes LR, van Berge Henegouwen JM, van der Wijngaart H, van der Velden DL, van Werkhoven E, Retel VP, van Harten WH, Huitema ADR, Timmers L, Gelderblom H, Verheul HMW, Voest EE. van Waalwijk van Doorn-Khosrovani SB, et al. Among authors: voest ee. Ann Oncol. 2019 May 1;30(5):663-665. doi: 10.1093/annonc/mdz119. Ann Oncol. 2019. PMID: 31038154 Free article. No abstract available.
330 results